Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

NCT ID: NCT01532102

Last Updated: 2018-05-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-02-28
• Study Completion Date: 2013-05-06

Brief Summary

The purpose of this study is to determine the safety, tolerability and efficacy of the topical application of AP611074 5% gel during 6 weeks on ano-genital warts caused by human papillomavirus (HPV).

Detailed Description

Genital warts (GW; also called condylomas or condylomata acuminata) are lesions caused by infection of Human papillomavirus (HPV)(specifically HPV-6 or HPV-11 types, found in > 95% of lesions). GW are sexually transmitted and affect about 1% of the sexually active population. GW represent a distressful condition for social and sexual life, especially in the cases of external condylomas. No HPV-specific antiviral treatment exists to date, and all existing therapies (either surgical or drug) have limited efficacy, with a significant level of GW recurrences and are associated with local skin reactions. AP611074 is a synthetic new chemical entity that is a potent and selective inhibitor of the interaction between two viral proteins from HPV6 and HPV11, an interaction that is a necessary step for HPV DNA replication and thus viral production. AP611074 is the "first in class" specific HPV antiviral described to treat condyloma caused by HPV infection.

Conditions

Anogenital Warts; Condylomata Acuminata; Human Papillomavirus Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

AP611074 5% gel

Twice daily application of 100 mg dose of AP611074 5% gel for 41 days followed by a single morning application on Day 42

Group Type: EXPERIMENTAL

AP611074

Intervention Type: DRUG

Placebo gel

Twice daily application of 100 mg dose of placebo gel for 41 days followed by a single morning application on Day 42

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo gel manufactured to appear identical to AP611074 5% gel

Interventions

AP611074

Intervention Type: DRUG

Placebo

Placebo gel manufactured to appear identical to AP611074 5% gel

Intervention Type: DRUG

Other Intervention Names

HPV antiviral; Anticondyloma drug

Eligibility Criteria

Inclusion Criteria

• Male or female patient aged between 18 and 55 years.
• External condylomas, 1-15 lesions, non-confluent and individually isolated.
• Lesions must not be internal (ie, they must not penetrate the urethral meatus, vagina or anal canal); their visualization must be complete by patients and investigators without major facilitation maneuvers and easily documented by digital pictures.
• Lesions should have a total surface smaller than 5 cm2, and an individual surface smaller than 1 cm2; lesions should be easily measured using a "French Catheter Scale".
• Lesions to be treated should have appeared between 1-6 months before screening and patients should not have received any previous condyloma treatment since their appearance.
• For patients having previous episodes of condyloma lesions, they shouldn't have received any condyloma treatment for at least 12 months before screening.

Exclusion Criteria

• Patients with any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease that, in the Investigator's judgment, prevents the patients from participating to the study.
• Patients with VIN or PIN (intraepithelial neoplasia of vulva or penis; ie, Bowenoid papulosis), or genital disease (ie, lichen sclerosus, lichen planus, lichen simplex chronicus, dermatitis, psoriasis, bullous diseases, systemic diseases with genital manifestations) requiring treatment.
• Patients with fibroepithelial polyps or scaly non-viral papillomas, seborrheic keratosis, follicular papules, syringoma, or circumscribed lymphangiomas.
• Patients whose skin condition or coloration would interfere with the observation and the follow-up of the lesions during the study.
• Patients for whom a proper follow-up of the lesions during the study will not be possible, because of hair growth in the treatment area.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Anaconda Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Olivier Chosidow, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

IADT - Instituto Argentino de Diagnostico y Tratamiento S.A.

Buenos Aires, , Argentina

Hospotal Italinao de Buenos Aires - Dept of Dermatology and Gynecology

Buenos Aires, , Argentina

Hopital Henri Mondor-Dept of Dermatology

Créteil, , France

SGS Aster

Paris, , France

Countries

Argentina; France

Other Identifiers

2011-003760-80

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

AP611074.CT3

Identifier Type: -

Identifier Source: org_study_id